Published in Emerg Infect Dis on March 01, 2017
An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med (2007) 33.18
Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med (1998) 32.43
The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. N Engl J Med (1985) 8.55
A comparison of the ability of different propensity score models to balance measured variables between treated and untreated subjects: a Monte Carlo study. Stat Med (2007) 6.48
Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies. Pharm Stat (2012) 5.35
Nontuberculous mycobacterial lung disease prevalence at four integrated health care delivery systems. Am J Respir Crit Care Med (2010) 3.83
Prevalence of nontuberculous mycobacterial lung disease in U.S. Medicare beneficiaries. Am J Respir Crit Care Med (2012) 2.44
Performance of the ACG case-mix system in two Canadian provinces. Med Care (2001) 2.27
Nontuberculous pulmonary mycobacteriosis in Denmark: incidence and prognostic factors. Am J Respir Crit Care Med (2009) 1.73
Risk of mycobacterial infections associated with rheumatoid arthritis in Ontario, Canada. Chest (2014) 1.57
Epidemiology of human pulmonary infection with nontuberculous mycobacteria: a review. Clin Chest Med (2014) 1.51
Prognostic factors of 634 HIV-negative patients with Mycobacterium avium complex lung disease. Am J Respir Crit Care Med (2011) 1.42
Pulmonary nontuberculous mycobacterial disease, Ontario, Canada, 1998-2010. Emerg Infect Dis (2013) 1.31
The reliability of diagnostic coding and laboratory data to identify tuberculosis and nontuberculous mycobacterial disease among rheumatoid arthritis patients using anti-tumor necrosis factor therapy. Pharmacoepidemiol Drug Saf (2010) 1.11
Population-based Incidence of Pulmonary Nontuberculous Mycobacterial Disease in Oregon 2007 to 2012. Ann Am Thorac Soc (2015) 1.08
Predictors of 5-year mortality in pulmonary Mycobacterium avium-intracellulare complex disease. Int J Tuberc Lung Dis (2012) 1.06
Nontuberculous mycobacterial lung infections in Ontario, Canada: clinical and microbiological characteristics. Lung (2010) 1.01
The cost of medical management of pulmonary nontuberculous mycobacterial disease in Ontario, Canada. Eur Respir J (2010) 0.97
Clinical and therapeutic features of pulmonary nontuberculous mycobacterial disease, Brazil, 1993-2011. Emerg Infect Dis (2013) 0.94
Mortality among patients with pulmonary non-tuberculous mycobacteria disease. Int J Tuberc Lung Dis (2016) 0.88
Comparison of the spectrum of radiologic and clinical manifestations of pulmonary disease caused by Mycobacterium avium complex and Mycobacterium xenopi. Can Assoc Radiol J (2013) 0.88
Impaired health-related quality of life in pulmonary nontuberculous mycobacterial disease. Respir Med (2011) 0.87
Prognostic value of American Thoracic Society criteria for non-tuberculous mycobacterial disease: a retrospective analysis of 120 cases with four years of follow-up. Scand J Infect Dis (2012) 0.79
Genome sequencing in microfabricated high-density picolitre reactors. Nature (2005) 150.21
A draft sequence of the rice genome (Oryza sativa L. ssp. indica). Science (2002) 42.78
Global mapping of the yeast genetic interaction network. Science (2004) 21.34
2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) (2012) 12.07
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis (2010) 10.03
RePS: a sequence assembler that masks exact repeats identified from the shotgun data. Genome Res (2002) 4.35
Active surveillance of small renal masses: progression patterns of early stage kidney cancer. Eur Urol (2011) 3.75
Tea polyphenol (-)-epigallocatechin-3-gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines. Cancer Res (2003) 3.72
Initiation of tumor necrosis factor-α antagonists and the risk of hospitalization for infection in patients with autoimmune diseases. JAMA (2011) 3.58
Outcomes of small renal mass needle core biopsy, nondiagnostic percutaneous biopsy, and the role of repeat biopsy. Eur Urol (2011) 3.51
Risk of Guillain-Barré syndrome after seasonal influenza vaccination and influenza health-care encounters: a self-controlled study. Lancet Infect Dis (2013) 3.27
Nontuberculous mycobacterial disease prevalence and risk factors: a changing epidemiology. Clin Infect Dis (2009) 3.09
Global asthma prevalence in adults: findings from the cross-sectional world health survey. BMC Public Health (2012) 3.01
Decreased postoperative endophthalmitis rate after institution of intracameral antibiotics in a Northern California eye department. J Cataract Refract Surg (2012) 2.95
miR-21 plays a pivotal role in gastric cancer pathogenesis and progression. Lab Invest (2008) 2.87
The geographic diversity of nontuberculous mycobacteria isolated from pulmonary samples: an NTM-NET collaborative study. Eur Respir J (2013) 2.80
N-substituted pyrrole derivatives as novel human immunodeficiency virus type 1 entry inhibitors that interfere with the gp41 six-helix bundle formation and block virus fusion. Antimicrob Agents Chemother (2004) 2.76
Purgative bowel cleansing combined with simethicone improves capsule endoscopy imaging. Am J Gastroenterol (2007) 2.73
Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases. JAMA (2012) 2.51
A report card to grade Helicobacter pylori therapy. Helicobacter (2007) 2.41
Trends in the aggressiveness of end-of-life cancer care in the universal health care system of Ontario, Canada. J Clin Oncol (2011) 2.31
Inhaled anticholinergic drug therapy and the risk of acute urinary retention in chronic obstructive pulmonary disease: a population-based study. Arch Intern Med (2011) 2.27
Systematic exploration of essential yeast gene function with temperature-sensitive mutants. Nat Biotechnol (2011) 2.26
Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide. Cell (2007) 2.22
Obesity and respiratory hospitalizations during influenza seasons in Ontario, Canada: a cohort study. Clin Infect Dis (2011) 2.17
Hypercholesterolemia stimulates angiotensin peptide synthesis and contributes to atherosclerosis through the AT1A receptor. Circulation (2004) 2.04
Detection of airborne severe acute respiratory syndrome (SARS) coronavirus and environmental contamination in SARS outbreak units. J Infect Dis (2005) 2.03
Inhalational anthrax outbreak among postal workers, Washington, D.C., 2001. Emerg Infect Dis (2002) 2.03
Identification of N-phenyl-N'-(2,2,6,6-tetramethyl-piperidin-4-yl)-oxalamides as a new class of HIV-1 entry inhibitors that prevent gp120 binding to CD4. Virology (2005) 2.03
Different from the HIV fusion inhibitor C34, the anti-HIV drug Fuzeon (T-20) inhibits HIV-1 entry by targeting multiple sites in gp41 and gp120. J Biol Chem (2005) 1.99
Geographic distribution of endemic fungal infections among older persons, United States. Emerg Infect Dis (2011) 1.94
Is a mass immunization program for pandemic (H1N1) 2009 good value for money? Evidence from the Canadian Experience. Vaccine (2010) 1.91
Obstructive sleep apnea and incident diabetes. A historical cohort study. Am J Respir Crit Care Med (2014) 1.86
Estimating influenza vaccine effectiveness in community-dwelling elderly patients using the instrumental variable analysis method. Arch Intern Med (2012) 1.86
Bone marrow transplantation reveals that recipient AT1a receptors are required to initiate angiotensin II-induced atherosclerosis and aneurysms. Arterioscler Thromb Vasc Biol (2006) 1.85
Disaccharide structure code for the easy representation of constituent oligosaccharides from glycosaminoglycans. Nat Methods (2008) 1.84
Nontuberculous mycobacterial sensitization in the United States: national trends over three decades. Am J Respir Crit Care Med (2007) 1.82
Two new complete genome sequences offer insight into host and tissue specificity of plant pathogenic Xanthomonas spp. J Bacteriol (2011) 1.80
Environment or host?: A case-control study of risk factors for Mycobacterium avium complex lung disease. Am J Respir Crit Care Med (2012) 1.78
Update on the epidemiology of pulmonary nontuberculous mycobacterial infections. Semin Respir Crit Care Med (2013) 1.78
Metabolic engineering of Escherichia coli using synthetic small regulatory RNAs. Nat Biotechnol (2013) 1.76
Proteomic fingerprints for potential application to early diagnosis of severe acute respiratory syndrome. Clin Chem (2004) 1.76
Design and evaluation of sifuvirtide, a novel HIV-1 fusion inhibitor. J Biol Chem (2008) 1.74
Influenza vaccination coverage across ethnic groups in Canada. CMAJ (2012) 1.71
Receptor-binding domain of severe acute respiratory syndrome coronavirus spike protein contains multiple conformation-dependent epitopes that induce highly potent neutralizing antibodies. J Immunol (2005) 1.70
Health care costs associated with hepatocellular carcinoma: a population-based study. Hepatology (2013) 1.63
The determinants of 2009 pandemic A/H1N1 influenza vaccination: a systematic review. Vaccine (2011) 1.61
Systematic identification of molecular subtype-selective vulnerabilities in non-small-cell lung cancer. Cell (2013) 1.60
Role of interferon-stimulated responsive element-like element in interleukin-8 promoter in Helicobacter pylori infection. Gastroenterology (2004) 1.59
Congenital lethal motor neuron disease with a novel defect in ribosome biogenesis. Neurology (2014) 1.59
HIV gp41 C-terminal heptad repeat contains multifunctional domains. Relation to mechanisms of action of anti-HIV peptides. J Biol Chem (2007) 1.58
The impact of infection on population health: results of the Ontario burden of infectious diseases study. PLoS One (2012) 1.58
Risk of mycobacterial infections associated with rheumatoid arthritis in Ontario, Canada. Chest (2014) 1.57
Stability, cellular uptake, biotransformation, and efflux of tea polyphenol (-)-epigallocatechin-3-gallate in HT-29 human colon adenocarcinoma cells. Cancer Res (2002) 1.57
Gene sequencing for routine verification of pyrazinamide resistance in Mycobacterium tuberculosis: a role for pncA but not rpsA. J Clin Microbiol (2012) 1.55
Theta-defensins prevent HIV-1 Env-mediated fusion by binding gp41 and blocking 6-helix bundle formation. J Biol Chem (2006) 1.54
Reduced microRNA-218 expression is associated with high nuclear factor kappa B activation in gastric cancer. Cancer (2010) 1.54
Chest computed tomography predicts microbiological burden and symptoms in pulmonary Mycobacterium xenopi. Respirology (2013) 1.49
Nontuberculous mycobacterial infection as a cause of difficult-to-control asthma: a case-control study. Chest (2010) 1.49
Therapy for Helicobacter pylori infection can be improved: sequential therapy and beyond. Drugs (2008) 1.48
Design of a protein surface antagonist based on alpha-helix mimicry: inhibition of gp41 assembly and viral fusion. Angew Chem Int Ed Engl (2002) 1.47
Variable agreement among experts regarding Mycobacterium avium complex lung disease. Respirology (2014) 1.47
Long-term cardiovascular risk in women prescribed fertility therapy. J Am Coll Cardiol (2013) 1.46
Postoperative pneumonia in elderly patients receiving acid suppressants: a retrospective cohort analysis. BMJ (2010) 1.44
Rates of hospitalized bacterial infection associated with juvenile idiopathic arthritis and its treatment. Arthritis Rheum (2012) 1.43
Safety of influenza vaccination in patients with myasthenia gravis: a population-based study. Muscle Nerve (2009) 1.41
Urinary and plasma levels of resveratrol and quercetin in humans, mice, and rats after ingestion of pure compounds and grape juice. J Agric Food Chem (2004) 1.40
Epigallocatechin-3-gallate is absorbed but extensively glucuronidated following oral administration to mice. J Nutr (2003) 1.40
Invasive Haemophilus influenzae disease caused by non-type b strains in Northwestern Ontario, Canada, 2002-2008. Clin Infect Dis (2009) 1.36
Conserved residue Lys574 in the cavity of HIV-1 Gp41 coiled-coil domain is critical for six-helix bundle stability and virus entry. J Biol Chem (2007) 1.34
First-in-human phase I dose-escalation study of the HSP90 inhibitor AUY922 in patients with advanced solid tumors. Clin Cancer Res (2013) 1.33
Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions. Ann Rheum Dis (2012) 1.33
Pulmonary nontuberculous mycobacterial disease, Ontario, Canada, 1998-2010. Emerg Infect Dis (2013) 1.31
Population-based incidence of herpes zoster after introduction of a publicly funded varicella vaccination program. Vaccine (2011) 1.31
Study design for a comprehensive assessment of biologic safety using multiple healthcare data systems. Pharmacoepidemiol Drug Saf (2011) 1.30
Invasive disease caused by Haemophilus influenzae type a in Northern Ontario First Nations communities. J Med Microbiol (2010) 1.30
Organic anion-transporting polypeptide 1b2 (Oatp1b2) is important for the hepatic uptake of unconjugated bile acids: Studies in Oatp1b2-null mice. Hepatology (2010) 1.29
Functional SNP in the microRNA-367 binding site in the 3'UTR of the calcium channel ryanodine receptor gene 3 (RYR3) affects breast cancer risk and calcification. Proc Natl Acad Sci U S A (2011) 1.28
Stem cell-delivery therapeutics for periodontal tissue regeneration. Biomaterials (2012) 1.27
Risk of incident diabetes in relation to long-term exposure to fine particulate matter in Ontario, Canada. Environ Health Perspect (2013) 1.26
Potent HIV fusion inhibitors against Enfuvirtide-resistant HIV-1 strains. Proc Natl Acad Sci U S A (2008) 1.25
Evaluation of Electronic Medical Record Administrative data Linked Database (EMRALD). Am J Manag Care (2014) 1.22
Identification of a critical motif for the human immunodeficiency virus type 1 (HIV-1) gp41 core structure: implications for designing novel anti-HIV fusion inhibitors. J Virol (2008) 1.20
The importance of nontuberculous mycobacterial lung disease. Am J Respir Crit Care Med (2008) 1.20
Design, synthesis, and biological evaluation of N-carboxyphenylpyrrole derivatives as potent HIV fusion inhibitors targeting gp41. J Med Chem (2008) 1.20
Selection of a novel gp41-specific HIV-1 neutralizing human antibody by competitive antigen panning. J Immunol Methods (2006) 1.19
Combination of candidate microbicides cellulose acetate 1,2-benzenedicarboxylate and UC781 has synergistic and complementary effects against human immunodeficiency virus type 1 infection. Antimicrob Agents Chemother (2005) 1.19
Efficacy of bismuth-containing quadruple therapies for clarithromycin-, metronidazole-, and fluoroquinolone-resistant Helicobacter pylori infections in a prospective study. Clin Gastroenterol Hepatol (2013) 1.19
Toxoplasmosis: a global threat. J Glob Infect Dis (2011) 1.19